XL820
- Generic Name
- XL820
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1123889-88-2
- Unique Ingredient Identifier
- -
- Background
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a varie...
- Indication
Investigated for use/treatment in solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
- Conditions
- Interventions
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 16
- Registration Number
- NCT00570635
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
- Conditions
- First Posted Date
- 2006-07-11
- Last Posted Date
- 2008-08-18
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 30
- Registration Number
- NCT00350831
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
Study of XL820 in Adults With Solid Tumors
- Conditions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Exelixis
- Registration Number
- NCT00129571
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.